LOS ALAMOS, NM, United States

Time filter

Source Type

Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 3.00M | Year: 2011

DESCRIPTION (provided by applicant): This Phase II project continues the successful Phase I discovery of novel decorporation agents that are selective for radioactive strontium (Sr). This project consists of the necessary steps for submission of an Emergency Use Authorization (EUA) or Investigational New Drug (IND) application to the US FDA. A goal is to have orally- administered, GI-chelation formulations ready for an FDA application by the end of year for the Strategic National Stockpile (SNS). This project is guided by the Guidance for Industry: Internal Radioactive Contamination -Development of Decorporation Agents. Sr-90 is easily obtained by terrorists;radioactive Sr-decorporation is a very high DHHS / NIH / NIAID / DAIT priority and treatments for Sr-90 exposure remain a critical need for the SNS. Sr-90 and its daughter yttrium-90 are beta emitters that deposit their energy in the body. Sr-90 is readily absorbed by both respiratory and GI routes and up to 50% of a dose will be deposited in bone. Current GI absorption blocking agents, such as aluminum phosphate, are of low effectiveness, although they are recommended for clinical use. There are no Sr-specific decorporation agents available. PUBLIC HEALTH RELEVANCE: This Phase II project continues the successful Phase I discovery of novel decorporation agents that are selective for radioactive strontium. A goal is to have orally-administered, GI-chelation formulations ready for an FDA application by the end of year for the Strategic National Stockpile. Sr-90 is easily obtained by terrorists; radioactive Sr-decorporation is a very high priority and treatments for Sr-90 exposure remain a critical need for the SNS.


Grant
Agency: Department of Defense | Branch: Air Force | Program: SBIR | Phase: Phase I | Award Amount: 150.00K | Year: 2012

ABSTRACT: Caldera Pharmaceuticals proposes to develop physiologic biomarkers requested by the US Air Force to quantify workplace exposure to hexavalent chrome (Cr+6). Exposure to Cr+6 is dangerous and unwanted, because it is a primary carcinogen (class 1 International Agency for Research on Cancer / IARC) and a known lung cancer carcinogen. Chromium (Cr) exists in several valence states, the most prevalent states are hexavalent Cr (Cr+6, which is associated with industrial exposure and toxicity) and trivalent Cr (Cr+3, which is stable and a biologically active form). Cr+3 is an essential nutrient for humans and shortages may cause heart conditions and metabolic disruptions or diabetes; it is classified as IARC Group 3. Although a limited amount of Cr+3 is necessary, large amounts may be hazardous. Cr supplements are taken readily and are available as trivalent Cr in chloride (CrCl3) or picolinate (CrPic) salt forms, but associated health effects are unknown. If ingested in large amounts, both Cr+3 and +6 can cause gastrointestinal problems and ulcers, or kidney and liver damage. There are no physiologic biomarkers for exposure to Cr+6, especially those that differentiate between various Cr species in vivo. Caldera XRpro(R) Technology will be used to screen for Cr-selective biomarker aptamers. BENEFIT: Military personnel are an important cohort that is exposed to Cr+6; accurate and inexpensive biomarker assays developed in the project may also be used for mitigation of exposure effects to personnel, and environmental monitoring/abatement. These increase the commercial appeal of the products. XRpro offers reagent availability and low cost that are key to the success of the products. Biomarker agents developed in Phase I have multiple usages including environmental monitoring and abatement, markers of exposure in vivo, therapeutic chelation of only dangerous metals, without harm to useful elements such as zinc and selenium. Drug and biomarker discovery/development costs are extremely expensive. The proposed project solves this problem by using low cost and better data acquisition methods provided by Caldera XRpro screening. Library screening is less expensive and provides better, full elemental data, resulting in more available, stable, and effective formulation, selectivity, sensitivity, and specificity. Many cellular factors are regulated through variable phosphorylation, metallation, and glycosylation. XRpro simultaneously assesses metal cofactors, collecting quantitative data on 24 elements such as sulfur (S, from peptides), calcium (Ca), zinc (Zn), selenium (Se), copper (Cu), iron (Fe), phosphorus (P), etc. No other available technology screens for metal selectivity so rapidly.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 98.92K | Year: 2010

DESCRIPTION (provided by applicant): Most cellular processes are regulated by reversible protein phosphorylation, which is controlled by protein kinases and phosphatases. Caldera Pharmaceuticals and MedChem Partners propose to develop new probes for characterizing transient protein complexes. MAPK pathways play important roles in cellular differentiation and survival. MAPKs are serine/threonine protein kinases that can phoshorylate both cytoplasmic and nuclear targets. MAPKs are associated with aberrant, chronic or hyper-phosphorylation found in cancerous and other diseased tissues. MAPK complexes are difficult to characterize due to the transient nature of kinase-substrate binding interactions. PUBLIC HEALTH RELEVANCE: Caldera Pharmaceuticals and MedChem Partners propose to develop new probes for characterizing transient protein complexes. MAPK complexes are difficult to characterize due to the transient nature of kinase-substrate binding interactions.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 200.00K | Year: 2010

DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. In Phase I, Caldera will demonstrate the feasibility of using its novel XRpro(R) technology to extract, concentrate, quantify, and characterize carcinogens from biological samples. This will also identify protein adduct biomarkers that are involved in critical carcinogenic and biotransformation pathways. This project addresses challenges listed in PA-09-187, including the measurement of carcinogens directly, without antibodies, dyes, tags, or radioactive materials. PUBLIC HEALTH RELEVANCE: Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. This project addresses challenges listed in PA-09-187, including the measurement of carcinogens directly, without antibodies, dyes, tags, or radioactive materials.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 300.00K | Year: 2015

Not Available


Patent
Los Alamos National Security LLC and Caldera Pharmaceuticals, Inc. | Date: 2012-10-17

There is described an apparatus for measuring protein characteristics comprising an X-ray fluorescence (XRF) spectrometer comprising a source of polychromatic X-rays, an X-ray detector, a protein, a molecule that has been exposed to and at least weakly binds to the protein, a plurality of X-ray fluorescence signal data obtained by irradiating chemical elements in the protein and molecule with the polychromatic X-rays and a security system for maintaining records for the data from the plurality of X-ray fluorescence signal measurements. There is also described an x-ray microscope for measuring a sample.


Patent
Caldera Pharmaceuticals, Inc. | Date: 2013-01-11

In accordance with various embodiments, a plug head assembly is provided comprising a ceramic plug head having a frustroconical geometry, wherein the ceramic plug head has a proximal terminus and a distal terminus, wherein the ceramic plug head has a first coefficient of thermal expansion (CTE), a sleeve having a frustroconical geometry conforming to the ceramic plug head and a second CTE, wherein the second CTE is greater than the first CTE, a distal retainer having a frustroconical geometry conforming to the sleeve, the distal retainer having a first engagement portion for engaging the a proximal retainer, the proximal retainer having a second engagement portion for engaging the distal retainer, and a base that couples with the proximal retainer. In addition, thick banded plug heads are provided.


Patent
Caldera Pharmaceuticals, Inc. | Date: 2012-08-06

An apparatus for preparing samples for measurement by x-ray fluorescence spectrometry. A plate has one or more holes passing through the plate. The holes are covered by a film on one side of the plate. The holes are less than 500 micrometers across in one dimension where the film covers the holes. The film is translucent to x-rays.


Patent
Caldera Pharmaceuticals, Inc. | Date: 2013-04-26

The present invention includes a method and apparatus for measuring the transport of analytes through a cell barrier.


Trademark
Caldera Pharmaceuticals, Inc. | Date: 2013-08-27

Downloadable scientific and medical data via the internet; Glassware for scientific experiments in laboratories; Plates, glass slides or chips having multi-well arrays that can be used in chemical analysis, biological analysis or patterning for scientific, laboratory or medical research use; Scientific apparatus and instruments for measuring relative DNA/RNA and protein and parts and fittings therefor; Scientific apparatus and instruments, namely, chromatography columns for use in purification in the laboratory and parts and fittings therefor; Scientific apparatus for use with membrane filtration, namely, water filter controllers and computer software for detecting and measuring water quality; Scientific apparatus, namely, spectrometers and parts and fittings therefor; Scientific apparatus, namely, spectrophotometer for measuring relative DNA/RNA and protein; Sensor chips for scientific use.

Loading Caldera Pharmaceuticals, Inc. collaborators
Loading Caldera Pharmaceuticals, Inc. collaborators